(2004). Bicalutamide (Casodex) in the treatment of prostate cancer. Expert Rev Anticancer Ther
(2008). CC: Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res
(2007). Choubey D: Expression of androgen receptor is negatively regulated by p53. Neoplasia
(2006). CJ: The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
(2005). Dahut WL: Androgen deprivation therapy for prostate cancer. JAMA
(2003). deVere White RW: Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res
(2009). DP: Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer
(1992). E: The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens.
(2000). et al: Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
(2004). et al: Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res
(1997). et al: Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgendependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol
(2004). et al: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science
(2006). et al: Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA
(2001). Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer
(1941). HC: Studies on prostate cancer. 1. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res
(2001). Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum Mol Genet
(2004). Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene
(1988). Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology
(2009). Isaacs JT: Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. Prostate
(2000). KR: Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res
(2001). L: p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction.
(2005). Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene
(2005). MB: Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene
(2008). MB: MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther